DOCSLIB.ORG

Bacterial Resistance to Antimicrobial Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bacterial Resistance to Antimicrobial Agents antibiotics Review Bacterial Resistance to Antimicrobial Agents Manuel F. Varela 1,* , Jerusha Stephen 2 , Manjusha Lekshmi 2, Manisha Ojha 1, Nicholas Wenzel 1, Leslie M. Sanford 1, Alberto J. Hernandez 1, Ammini Parvathi 3 and Sanath H. Kumar 2 1 Department of Biology, Eastern New Mexico University, Portales, NM 88130, USA; [email protected] (M.O.); [email protected] (N.W.); [email protected] (L.M.S.); [email protected] (A.J.H.) 2 Post-Harvest Technology, ICAR-Central Institute of Fisheries Education, Seven Bungalows, Andheri (W), Mumbai 400061, India; [email protected] (J.S.); [email protected] (M.L.); [email protected] (S.H.K.) 3 CSIR-National Institute of Oceanography, Regional Centre, Kochi 682018, India; [email protected] * Correspondence: [email protected] Abstract: Bacterial pathogens as causative agents of infection constitute an alarming concern in the public health sector. In particular, bacteria with resistance to multiple antimicrobial agents can confound chemotherapeutic efficacy towards infectious diseases. Multidrug-resistant bacteria harbor various molecular and cellular mechanisms for antimicrobial resistance. These antimicrobial resistance mechanisms include active antimicrobial efflux, reduced drug entry into cells of pathogens, enzymatic metabolism of antimicrobial agents to inactive products, biofilm formation, altered drug targets, and protection of antimicrobial targets. These microbial systems represent suitable focuses for investigation to establish the means for their circumvention and to reestablish therapeutic effec- tiveness. This review briefly summarizes the various antimicrobial resistance mechanisms that are harbored within infectious bacteria. Citation: Varela, M.F.; Stephen, J.; Lekshmi, M.; Ojha, M.; Wenzel, N.; Keywords: bacteria; antimicrobial resistance; infection; pathogenesis; multidrug resistance Sanford, L.M.; Hernandez, A.J.; Parvathi, A.; Kumar, S.H. Bacterial Resistance to Antimicrobial Agents. Antibiotics 2021, 10, 593. https:// 1. Introduction doi.org/10.3390/antibiotics10050593 Bacteria as microbial pathogens are causative agents of life-threatening infectious dis- eases [1]. Such pathogenic bacteria produce alarming numbers in terms of morbidity and Academic Editor: Nahed El-Najjar mortality outcomes [2,3]. One crucial avenue towards bacterial pathogenesis involves the reduction in the therapeutic effects of antibacterial chemotherapy [4,5]. Throughout their Received: 22 April 2021 evolutionary history, bacterial pathogens have developed various means of resisting the Accepted: 14 May 2021 Published: 17 May 2021 inhibitory and bactericidal consequences of antimicrobial agents [4]. Such antimicrobial resistance systems involve the engagement of bacterial molecular and cellular-based ma- Publisher’s Note: MDPI stays neutral chinery [6]. Interestingly, the selection of a bacterial variant with resistance to a single with regard to jurisdictional claims in antimicrobial agent frequently manifests the emergence of a multidrug resistance character- published maps and institutional affil- istic in the new mutant [7]. Newly emerged bacterial pathogens with resistance to multiple iations. antibacterial agents can result in compromised efficacy in the treatment of infection [3,8]. Mechanisms of antimicrobial resistance include the active export systems within the membranes of bacteria, prevention of antimicrobial entrance into cells of pathogenic bacteria, enzymatic destruction of antimicrobial agents, production of thick biofilms, modified tar- gets of antimicrobials, and bacterial sites of action that are protected from antimicrobials, Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. (Figure1) [2,4]. Furthermore, multidrug-resistant bacteria have developed mechanisms that This article is an open access article confer the DNA transfer of genetic determinants of resistance to pathogenic species in the distributed under the terms and clinical setting, the food production industry, the human gut, and in agriculture [9]. conditions of the Creative Commons Thus, new strategies for the circumvention of bacterial resistance to antimicrobial Attribution (CC BY) license (https:// agents are desired [10]. In order to discover novel approaches to address multiple an- creativecommons.org/licenses/by/ timicrobial resistances in these microbial pathogens, however, it is necessary to attain 4.0/). a clear understanding of these resistance systems at the molecular and cellular levels. Antibiotics 2021, 10, 593. https://doi.org/10.3390/antibiotics10050593 https://www.mdpi.com/journal/antibiotics Antibiotics 2021, 10, 593 2 of 22 Antibiotics 2021, 10, x FOR PEER REVIEW For young and new investigators, here, we consider an introductory overview2 of 22 of each of these disparate bacterial resistance mechanisms here. Figure 1. BacterialFigure mechanisms 1. Bacterial of mechanisms resistance toof antimicrobialresistance to antimicrobial agents. The commonagents. The mechanisms common mechanisms of antibiotic of resistance antibiotic resistance in bacteria are enzymatic hydrolysis (1), enzymatic modifications of antibiot- in bacteria are enzymatic hydrolysis (1), enzymatic modifications of antibiotics by group transfer and redox process (2), ics by group transfer and redox process (2), modifications of antibiotic targets (3), reduced perme- modifications of antibiotic targets (3), reduced permeability to antibiotics by modifications of porins (4), and active extrusion ability to antibiotics by modifications of porins (4), and active extrusion of antibiotics by mem- of antibiotics bybrane membrane efflux pumps efflux pumps (5). (5). Thus, new2. Enzyme-Based strategies for Antimicrobial-Inactivationthe circumvention of bacterial Systems resistance to antimicrobial agents are desired [10]. In order to discover novel approaches to address multiple antimi- Along the timeline of antibiotic discovery and introduction, several enzymatic mecha- crobial resistances in these microbial pathogens, however, it is necessary to attain a clear nisms of antibiotic inactivation were also discovered. Although very few novel mechanisms understanding of these resistance systems at the molecular and cellular levels. For young of antibiotic resistance have been reported in recent times, several new variants of known and new investigators, here, we consider an introductory overview of each of these dis- enzymes that endow bacteria with resistance to newly introduced drugs have emerged, parate bacterial resistance mechanisms here. suggesting that the bacterial response to new antibiotics or the modified versions of existing antibiotics is swift. The enzymatic mechanisms of antibiotic resistance include hydroly- 2. Enzyme-Based Antimicrobial-Inactivation Systems sis, group transfer, and redox processes [4]. In terms of diversity, evolution, and spread, Along theantibiotic timeline resistance of antibiotic enzymes discovery contribute and introduction, remarkably several to the bacterialenzymatic ability mech- to overcome anisms of antibioticantibiotic inactivation pressure. The wereβ-lactamases also discovered. are the Although oldest known very and few the novel most mecha- diverse antibiotic nisms of antibioticdegrading resistance enzymes have that been cleave reported the β in-lactam recent ringtimes, of several the penicillin new variants group of antibiotics known enzymesand render that endow them ineffective.bacteria with The resistance first such toβ -lactamasenewly introdu wasced discovered drugs have soon after the emerged, suggestingfirst antibiotic that penicillinthe bacterial was response in clinical to use.new Scientificantibiotics evidence or the modified suggests thever- existence of sions of existingβ-lactamases antibiotics before is swift. penicillin The enzymatic was clinically mechanisms employed, of emphasizing antibiotic resistance that the production include hydrolysis,of antimicrobial group transfer, compounds and redox and the processes mechanisms [4]. In to terms endure of themdiversity, occur evolu- in parallel in the tion, and spread,environment antibiotic [11 resistance]. Bacteria enzymes that produce contribute antibiotics remarkably apparently to the bacterial require abil- mechanisms to ity to overcomeovercome antibiotic the lethalpressure. effects The ofβ- thelactamases compounds, are the and oldest these known are in and the the form most of concurrent diverse antibioticproduction degrading of degradative enzymes that enzymes, cleave mutations the β-lactam in targets ring of of the antibiotics, penicillin or group active extrusion of antibioticsof and antibiotics render them from ineffective. the cell so The that first the such antibiotic-producing β-lactamase was celldiscovered is protected. soon However, after the firstthe antibiotic selection penicillin pressure createdwas in dueclinical to the use. extensive Scientific use evidence of antibiotics suggests in humans the ex- and animals istence of β-lactamases before penicillin was clinically employed, emphasizing that the production of antimicrobial compounds and the mechanisms to endure them occur in parallel in the environment [11]. Bacteria that produce antibiotics apparently require mechanisms to overcome the lethal effects of the compounds, and these are in the form of Antibiotics 2021, 10, 593 3 of 22 propagated the resistant clones of bacteria in clinical and food production environments. In due course of time, genetic exchange mechanisms facilitated the wider dissemination
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • Mechanisms and Strategies to Overcome Multiple Drug Resistance in Cancer
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 580 (2006) 2903–2909 Minireview Mechanisms and strategies to overcome multiple drug resistance in cancer Tomris Ozben* Akdeniz University, Faculty of Medicine, Department of Biochemistry, 07070 Antalya, Turkey Received 30 January 2006; accepted 9 February 2006 Available online 17 February 2006 Edited by Horst Feldmann The cytotoxic drugs that are most frequently associated with Abstract One of the major problems in chemotherapy is multi- drug resistance (MDR) against anticancer drugs. ATP-binding MDR are hydrophobic, amphipathic natural products, such as cassette (ABC) transporters are a family of proteins that medi- the taxanes (paclitaxel and docetaxel), vinca alkaloids (vinorel- ate MDR via ATP-dependent drug efflux pumps. Many MDR bine, vincristine, and vinblastine), anthracyclines (doxorubicin, inhibitors have been identified, but none of them have been pro- daunorubicin, and epirubicin), epipodophyllotoxins (etoposide ven clinically useful without side effects. Efforts continue to dis- and teniposide), antimetabolites (methorexate, fluorouracil, cover not toxic MDR inhibitors which lack pharmacokinetic cytosar, 5-azacytosine, 6-mercaptopurine, and gemcitabine) interactions with anticancer drugs. Novel approaches have also topotecan, dactinomycin, and mitomycin C [4,6–8]. been designed to inhibit or circumvent MDR. In this review, Overexpression of ATP-binding cassette (ABC) transporters the structure and function of ABC transporters and development has been shown to be responsible for MDR [5]. Therefore eluci- of MDR inhibitors are described briefly including various ap- dation of the structure and function for each ABC transporter is proaches to suppress MDR mechanisms.
    [Show full text]
  • Chapter 12 Antimicrobial Therapy Antibiotics
    Chapter 12 Antimicrobial Therapy Topics: • Ideal drug - Antimicrobial Therapy - Selective Toxicity • Terminology - Survey of Antimicrobial Drug • Antibiotics - Microbial Drug Resistance - Drug and Host Interaction An ideal antimicrobic: Chemotherapy is the use of any chemical - soluble in body fluids, agent in the treatment of disease. - selectively toxic , - nonallergenic, A chemotherapeutic agent or drug is any - reasonable half life (maintained at a chemical agent used in medical practice. constant therapeutic concentration) An antibiotic agent is usually considered to - unlikely to elicit resistance, be a chemical substance made by a - has a long shelf life, microorganism that can inhibit the growth or - reasonably priced. kill microorganisms. There is no ideal antimicrobic An antimicrobic or antimicrobial agent is Selective Toxicity - Drugs that specifically target a chemical substance similar to an microbial processes, and not the human host’s. antibiotic, but may be synthetic. Antibiotics Spectrum of antibiotics and targets • Naturally occurring antimicrobials – Metabolic products of bacteria and fungi – Reduce competition for nutrients and space • Bacteria – Streptomyces, Bacillus, • Molds – Penicillium, Cephalosporium * * 1 The mechanism of action for different 5 General Mechanisms of Action for antimicrobial drug targets in bacterial cells Antibiotics - Inhibition of Cell Wall Synthesis - Disruption of Cell Membrane Function - Inhibition of Protein Synthesis - Inhibition of Nucleic Acid Synthesis - Anti-metabolic activity Antibiotics
    [Show full text]
  • Antibiotic Resistance: from the Bench to Patients
    antibiotics Editorial Antibiotic Resistance: From the Bench to Patients Márió Gajdács 1,* and Fernando Albericio 2,3 1 Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Dóm tér 10., 6720 Szeged, Hungary 2 School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa 3 Department of Organic Chemistry, University of Barcelona, CIBER-BBN, 08028 Barcelona, Spain * Correspondence: [email protected]; Tel.: +36-62-341-330 Received: 20 August 2019; Accepted: 26 August 2019; Published: 27 August 2019 The discovery and subsequent clinical introduction of antibiotics is one of the most important game-changers in the history of medicine [1]. These drugs have saved millions of lives from infections that would previously have been fatal, and later, they allowed for the introduction of surgical interventions, organ transplantation, care of premature infants, and cancer chemotherapy [2]. Nevertheless, the therapy of bacterial infections is becoming less and less straightforward due to the emergence of multidrug resistance (MDR) in these pathogens [3]. Direct consequences of antibiotic resistance include delays in the onset of the appropriate (effective) antimicrobial therapy, the need to use older, more toxic antibiotics (e.g., colistin) with a disadvantageous side-effect profile, longer hospital stays, and an increasing burden on the healthcare infrastructure; overall, a decrease in the quality-of-life (QoL) and an increase in the mortality rate of the affected patients [4,5]. To highlight the severity of the issue, several international declarations have been published to call governments around the globe to take action on antimicrobial resistance [6–9]. Since the 1980s, pharmaceutical companies have slowly turned away from antimicrobial research and towards the drug therapy of chronic non-communicable diseases [10,11].
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • DESCRIPTION CLINICAL PHARMACOLOGY Mechanism Of
    NDA 20-844/ Topamav Sprinkle Capsules Approved Labeling Text Version: 10/26/98 DESCRIPTION Topiramate is a sulfamate-substituted monosaccharide that is intended for use as an antiepileptic drug. TOPAMAX@ (topiramate capsules) Sprinkle Capsules are available as I5 mg, 25 mg and 50mg sprinkle capsules for oral administration as whole capsules or for opening and sprinkling onto soft food. Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and hawng a pH of 9 to IO. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C,,H,,NO,S and a molecular weight of 339.37. Topiramate is designated chemically as 2,3:4,5-Di-O-isopropylidene-~- D-fructopyranose sulfamate and has the following structural formula: H3C CH3 TOPAMAX” (topiramate capsules) Sprinkle Capsules contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, silicone dioxide, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink. CLINICAL PHARMACOLOGY Mechanism of Action: The precise mechanism by which topiramate exerts its antiseizure effect is unknown; however, electrophysiological and biochemical studies of the effects of topiramate on cultured neurons have revealed three properties that may contribute to topiramate’s antiepileptic efficacy. First, action potentials elicited repetitively by a sustained depolarization of the neurons are blocked by topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking action.
    [Show full text]
  • Moving Beyond Single Gene-Drug Pairs in Clinical Pharmacogenomics Testing
    Moving Beyond Single Gene-Drug Pairs in Clinical Pharmacogenomics Testing Yuan Ji, PhD, DABCP, FACMG Gwendolyn McMillin, PhD, DABCC Learning Objectives • Describe the strengths and limitations of pharmacogenomic testing. • List examples of single gene-drug associations with the strongest levels of evidence for clinical implementation. • Discuss cautions when considering the use of multi-gene drug associations to inform drug therapy decisions. 2 Disclosure • None 3 Outline • Singe gene-drug based pharmacogenomics (PGx) testing – An introduction – Evidence and examples – Considerations for developing and evaluating clinical PGx laboratory developed tests (LDTs) • Multi-gene PGx panels – Evidence and examples – PROs and CONs for utilizing PGx panels – Considerations for successful PGx implementation 4 Single Gene-Drug Based PGx Testing Yuan Ji, PhD, DABCP, FACMG Medical Director of Genomics and Genetics; PGx, ARUP Laboratories Associate Professor (Clinical) of Pathology, University of Utah Medications: Myths and Facts • are~30% peoplenot take“one at least-size one medication fits all” within a 30-day period • Most medications cause adverse drug events (ADEs) • Some medications like antibiotics may do more harm than good • CDC statistics: – ~ 200,000 ADEs-related ER visits in pediatric population (17 years or younger) – ~ 450,000 ADEs-related ER visits in older adults (65 years or older) – Medications, e.g., anticoagulant warfarin • Many ADEs are preventable by closely supervising of dosing, blood tests (therapeutic drug monitoring, TDM),
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Natural Products As Alternative Choices for P-Glycoprotein (P-Gp) Inhibition
    Review Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition Saikat Dewanjee 1,*, Tarun K. Dua 1, Niloy Bhattacharjee 1, Anup Das 2, Moumita Gangopadhyay 3, Ritu Khanra 1, Swarnalata Joardar 1, Muhammad Riaz 4, Vincenzo De Feo 5,* and Muhammad Zia-Ul-Haq 6,* 1 Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India; [email protected] (T.K.D.); [email protected] (N.B.); [email protected] (R.K.); [email protected] (S.J.) 2 Department of Pharmaceutical Technology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 3 Department of Bioechnology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 4 Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan; [email protected] 5 Department of Pharmacy, Salerno University, Fisciano 84084, Salerno, Italy 6 Environment Science Department, Lahore College for Women University, Jail Road, Lahore 54600, Pakistan * Correspondence: [email protected] (S.D.); [email protected] (V.D.F.); [email protected] (M.Z.-U.-H.) Academic Editor: Maria Emília de Sousa Received: 11 April 2017; Accepted: 15 May 2017; Published: 25 May 2017 Abstract: Multidrug resistance (MDR) is regarded as one of the bottlenecks of successful clinical treatment for numerous chemotherapeutic agents. Multiple key regulators are alleged to be responsible for MDR and making the treatment regimens ineffective. In this review, we discuss MDR in relation to P-glycoprotein (P-gp) and its down-regulation by natural bioactive molecules. P-gp, a unique ATP-dependent membrane transport protein, is one of those key regulators which are present in the lining of the colon, endothelial cells of the blood brain barrier (BBB), bile duct, adrenal gland, kidney tubules, small intestine, pancreatic ducts and in many other tissues like heart, lungs, spleen, skeletal muscles, etc.
    [Show full text]
  • Hickman Catheter-Related Bacteremia with Kluyvera
    Jpn. J. Infect. Dis., 61, 229-230, 2008 Short Communication Hickman Catheter-Related Bacteremia with Kluyvera cryocrescens: a Case Report Demet Toprak, Ahmet Soysal, Ozden Turel, Tuba Dal1, Özlem Özkan1, Guner Soyletir1 and Mustafa Bakir* Department of Pediatrics, Section of Pediatric Infectious Diseases and 1Department of Microbiology, Marmara University School of Medicine, Istanbul, Turkey (Received September 10, 2007. Accepted March 19, 2008) SUMMARY: This report describes a 2-year-old child with neuroectodermal tumor presenting with febrile neu- tropenia. Blood cultures drawn from the peripheral vein and Hickman catheter revealed Kluyvera cryocrescens growth. The Hickman catheter was removed and the patient was successfully treated with cefepime and amikacin. Isolation of Kluyvera spp. from clinical specimens is rare. This saprophyte microorganism may cause serious central venous catheter infections, especially in immunosuppressed patients. Clinicians should be aware of its virulence and resistance to many antibiotics. Central venous catheters (CVCs) are frequently used in confirmed by VITEK AMS (VITEK Systems, Hazelwood, Mo., patients with hematologic and oncologic disorders. Along with USA) and by API (Analytab Inc., Plainview, N.Y., USA). Anti- their increased use, short- and long-term complications of microbial susceptibility was assessed by the disc diffusion CVCs are more often being reported. The incidence of CVC method. K. cryocrescens was sensitive for cefotaxime, cefepime, infections correlates with duration of catheter usage, immuno- carbapenems, gentamycine, amikacin and ciprofloxacin. logic status of the patient, type of catheter utilized and mainte- Intravenous cefepime and amikacin were continued and the nance techniques employed. A definition of CVC infection CVC was removed. His echocardiogram was normal and has been difficult to establish because of problems differen- a repeat peripheral blood culture was sterile 48 h after the tiating contaminant from pathogen microorganisms.
    [Show full text]
  • Cell Volume Change Through Water Efflux Impacts Cell Stiffness And
    Cell volume change through water efflux impacts cell PNAS PLUS stiffness and stem cell fate Ming Guoa,1, Adrian F. Pegoraroa, Angelo Maoa,b, Enhua H. Zhouc,2, Praveen R. Aranyd,e, Yulong Hana,f, Dylan T. Burnetteg, Mikkel H. Jensena,h, Karen E. Kaszaa,i, Jeffrey R. Moorej, Frederick C. Mackintoshk,l,m, Jeffrey J. Fredbergc, David J. Mooneya,b, Jennifer Lippincott-Schwartzn,3, and David A. Weitza,o,3 aJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138; bWyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, MA 02138; cHarvard T. H. Chan School of Public Health, Boston, MA 02115; dDepartment of Oral Biology, University at Buffalo, Buffalo, NY 14214; eDepartment of Biomedical Engineering, University at Buffalo, Buffalo, NY 14214; fBiomedical Engineering and Biomechanics Center, Xi’an Jiaotong University, Xi’an 710049, China; gDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232; hDepartment of Physics and Astronomy, California State University, Sacramento, CA 95819; iDepartment of Mechanical Engineering, Columbia University, New York, NY 10027; jDepartment of Biological Sciences, University of Massachusetts at Lowell, Lowell, MA 01854; kDepartment of Physics and Astronomy, VU University, 1081 HV Amsterdam, The Netherlands; lDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, TX 77030; mCenter for Theoretical Biophysics, Rice University, Houston, TX 77030; nHoward Hughes Medical Institute, Janelia Research Campus, Ashburn, VA 20147; and oDepartment of Physics, Harvard University, Cambridge, MA 02138 Contributed by Jennifer Lippincott-Schwartz, August 26, 2017 (sent for review March 29, 2017; reviewed by Daniel A. Fletcher and Valerie M.
    [Show full text]
  • Pharmacogenetic Testing: a Tool for Personalized Drug Therapy Optimization
    pharmaceutics Review Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization Kristina A. Malsagova 1,* , Tatyana V. Butkova 1 , Arthur T. Kopylov 1 , Alexander A. Izotov 1, Natalia V. Potoldykova 2, Dmitry V. Enikeev 2, Vagarshak Grigoryan 2, Alexander Tarasov 3, Alexander A. Stepanov 1 and Anna L. Kaysheva 1 1 Biobanking Group, Branch of Institute of Biomedical Chemistry “Scientific and Education Center”, 109028 Moscow, Russia; [email protected] (T.V.B.); [email protected] (A.T.K.); [email protected] (A.A.I.); [email protected] (A.A.S.); [email protected] (A.L.K.) 2 Institute of Urology and Reproductive Health, Sechenov University, 119992 Moscow, Russia; [email protected] (N.V.P.); [email protected] (D.V.E.); [email protected] (V.G.) 3 Institute of Linguistics and Intercultural Communication, Sechenov University, 119992 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-499-764-9878 Received: 2 November 2020; Accepted: 17 December 2020; Published: 19 December 2020 Abstract: Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician’s ability to understand the obtained results in a standardized way for each particular patient.
    [Show full text]